Copaxone (Glatiramer)

This is a medicine used to treat a condition called multiple sclerosis. It's a special type of protein that helps protect the nerves in the body. It's taken regularly, usually by injection, to help manage the symptoms of the disease.

Brand names:Copaxone, Glatopa
Medication

What people taking Copaxone (Glatiramer) report

Every report comes from a Lived member, sent anonymously.

Have you tried Copaxone (Glatiramer) for Relapsing-Remitting Multiple Sclerosis?

NameHow it went

About Copaxone (Glatiramer)

What It's For

Glatiramer acetate, best known by the brand name Copaxone, is a prescription injection for adults with relapsing forms of multiple sclerosis (MS). In MS, the immune system attacks myelin, the protective coating around nerve cells in the brain and spinal cord. That damage slows or blocks nerve signals and causes symptoms such as vision problems, numbness, weakness, fatigue or trouble with balance. Glatiramer is a disease-modifying therapy: it is taken long term to reduce new attacks and new inflammation, not to relieve day-to-day symptoms. Its approved uses cover three relapsing forms of MS. Clinically isolated syndrome is a first episode of MS-like symptoms lasting at least 24 hours, which may or may not develop into MS. Relapsing-remitting MS, the most common type, involves flare-ups of new or worsening symptoms (relapses) followed by periods of recovery. Active secondary progressive MS is a later stage in which symptoms slowly worsen but relapses or new inflammation still occur. Glatiramer is not approved for primary progressive MS, which worsens steadily from the start without clear relapses, and its safety and effectiveness in people under 18 have not been established. Copaxone was first approved in the US in 1996. Glatopa and other generic glatiramer acetate injections contain the same active ingredient in the same two strengths. Glatiramer reduces relapses by a moderate amount, about as much as interferon beta-1a, another long-established MS medicine. Some other disease-modifying medicines, such as natalizumab and cladribine, reduce relapses more, so choosing among them means weighing how well each works against its risks, monitoring needs and how it is taken.

How It Works

Glatiramer acetate is a laboratory-made mixture of small protein chains built from four amino acids, the building blocks of proteins. Exactly how it helps in MS is not fully understood. The leading explanation is that it changes the immune processes thought to drive the disease. Animal and laboratory studies suggest it prompts the body to produce regulatory immune cells (suppressor T cells) that can quiet the immune attack on myelin. In clinical trials, people taking glatiramer had fewer relapses and fewer new or active areas of inflammation (lesions) on magnetic resonance imaging (MRI) scans of the brain than people taking a placebo. These effects were measured over one to two years of treatment, which is why its benefit is judged over the long term rather than felt after a dose.

Dosage & Administration

Glatiramer is injected just under the skin (a subcutaneous injection) from a single-use prefilled syringe. It comes in two strengths with different schedules: 20 mg/mL is injected once a day, and 40 mg/mL is injected three times a week, with at least 48 hours between doses. The two strengths are not interchangeable, so the schedule has to match the strength prescribed. Copaxone, Glatopa and generic versions all come in these two strengths. The first injection is given with a nurse or other health professional present, often someone who also teaches injection technique. After that, people usually inject themselves, choosing a different injection area each time among the arms, abdomen, hips and thighs. Syringes are stored in the refrigerator and left at room temperature for about 20 minutes before injecting. If refrigeration is not possible, they can be kept at room temperature for up to one month. Some glatiramer products can be used with an optional autoinjector, a device that inserts the needle and delivers the dose at the push of a button. An autoinjector that is not made for the specific product can deliver only part of the dose or none at all, so check compatibility with the pharmacist, especially after a switch between Copaxone and a generic.

Side Effects

Injection site reactions are the most common side effect: redness, pain, itching, swelling or a lump where the needle went in. In trials of the daily dose, flushing (warmth and redness of the face or body), rash, shortness of breath and chest pain were also more common than with placebo. Apart from injection site reactions, these effects were reported less often in the trial of the three-times-weekly dose. Some people have an immediate post-injection reaction within seconds to minutes of an injection, with flushing, chest pain, a pounding or racing heart, anxiety or hives. It usually passes on its own and can first appear months after starting treatment. Brief episodes of chest pain can also happen on their own, usually starting a month or more into treatment. Call the prescriber right away after a post-injection reaction or chest pain, and do not inject again until they say it is safe to. Repeated injections can cause lipoatrophy, a loss of fat under the skin that leaves a dent and is thought to be permanent. Rarely, skin at an injection site dies (necrosis). Following the injection technique you were taught and rotating sites with every injection lowers the risk. Liver injury, including liver failure, has also been reported, from days to years after starting. Call the care team promptly about yellowing of the skin or eyes, dark urine or pale stools, or unexplained nausea, loss of appetite or tiredness. Serious allergic reactions (anaphylaxis) are rare but can be fatal, and they are the subject of the medicine's boxed warning, the most prominent safety alert from the US Food and Drug Administration (FDA). They can happen after the first dose or years into treatment, most often within an hour of an injection, and early symptoms can resemble an ordinary post-injection reaction. Call 911 for swelling of the face, lips, tongue or throat; sudden trouble breathing or wheezing; trouble swallowing or speaking; a widespread rash; fainting or feeling faint; or convulsions. After anaphylaxis, glatiramer is stopped permanently unless another cause is clearly identified.

Interactions & Warnings

Glatiramer should not be used by anyone who has had an allergic reaction to glatiramer acetate or to mannitol, an inactive ingredient in the injection. The prescribing information lists no specific drug interactions. Even so, the prescriber and pharmacist should know about every prescription and over-the-counter medicine, vitamin and supplement you take. Because glatiramer alters immune activity, it could in theory affect how the body fights infections or detects cancer cells. There is no evidence that it does, but this has not been formally studied. Pregnancy data gathered over decades of use have not shown a higher rate of birth defects or miscarriage linked to glatiramer, although the studies behind that finding have limitations. Very little of the drug reaches the bloodstream, so breastfeeding is not expected to expose the baby to meaningful amounts. Anyone who is pregnant, planning a pregnancy or breastfeeding should plan their MS treatment with the care team.

What to Expect

Glatiramer does not make existing MS symptoms go away, and day to day it may feel as if nothing has changed. Its benefit shows up over time as fewer relapses and less new inflammation on MRI. In the main trial of the three-times-weekly dose, people had about a third fewer confirmed relapses over a year than people on placebo. In people with clinically isolated syndrome, about 25% of those taking glatiramer had a second attack within three years, compared with about 43% of those on placebo. Injection site reactions, flushing, shortness of breath and hives were the side effects that most often led people in trials to stop treatment, though only about 5% stopped for side effects. Regular follow-up with the MS team helps judge whether the disease is staying under control. If relapses or new disease activity continue despite treatment, guidelines support discussing a switch to another disease-modifying therapy. Stopping or changing treatment is a decision to make with the MS team rather than on your own.

Questions to Ask Your Doctor

  1. 1.Given how my MS has behaved so far, why is glatiramer a better fit for me than a medicine that reduces relapses more?
  2. 2.Should I use the daily 20 mg dose or the three-times-weekly 40 mg dose, and is there an autoinjector that works with my product?
  3. 3.How will we tell whether it is working, and what would make us consider switching?
  4. 4.How can I tell an ordinary post-injection reaction from a serious allergic reaction, and what should I do for each?
  5. 5.How should we plan my treatment around pregnancy or breastfeeding?

Last reviewed • Oct 2026

Educational content, not medical advice.